[Drug research in oncology; advances in the genome era]

Area of Science:

• Oncology
• Genetics
• Clinical Pharmacology

Background:

• Genetic diagnostics are increasingly integrated into oncological clinical practice.
• Specific genetic aberrations allow for the sub-classification of solid tumors based on histological origin.
• This sub-classification drives the development of targeted therapies for specific genetic changes.

Purpose of the Study:

• To improve the efficiency of clinical research for targeted cancer therapies.
• To facilitate genome studies of tumors and clinical oncology studies.
• To accelerate the development of novel oncological drugs.

Main Methods:

• Utilizing genetic diagnostics for tumor sub-classification.
• Conducting clinical research in genetically characterized patient groups.
• Establishing a network for genome studies and clinical oncology (Center for Personalized Cancer Treatment).

Main Results:

• New possibilities for genetic diagnostics are emerging in oncological practice.
• Tumor sub-classification based on genetic aberrations is leading to targeted therapies.
• Challenges in identifying genetic aberrations due to tumor genome heterogeneity exist in primary tumors and metastases.

Conclusions:

• Genetic diagnostics offer new avenues for cancer treatment and drug development.
• Efficient clinical trials require genetically characterized patient cohorts.
• Collaborative networks are crucial for advancing personalized cancer treatment and drug development.